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Thrombomodulin Promotes Diabetic Wound Healing
by Regulating Toll-Like Receptor 4 Expression
Tsung-Lin Cheng1,2, Chao-Han Lai3, Po-Ku Chen4, Chia-Fong Cho4, Yun-Yan Hsu4, Kuan-Chieh Wang5,
Wei-Ling Lin4, Bi-Ing Chang3,4, Shi-Kai Liu4, Yu-Ting Wu4, Chao-Kai Hsu6, Guey-Yueh Shi3,4 and
Hua-Lin Wu3,4
Keratinocyte-expressed thrombomodulin (TM) and the released soluble TM (sTM) have been demonstrated to
promote wound healing. However, the effects of high glucose on TM expression in keratinocytes and the role of
TM in diabetic ulcer remain unclear. In this study, we demonstrated that expressions of TM and Toll-like receptor
4 (TLR4) were both downregulated in high-glucose cultured human keratinocytes and in skin keratinocytes of
diabetic patients. In addition, the wound-triggered upregulation of TM and sTM production was abolished in
both high-glucose cultured human keratinocytes and streptozotocin-induced diabetic mouse skin. Furthermore,
supplementation of recombinant sTM could increase TLR4 expression and promote cutaneous wound healing in
both high-glucose cultured human keratinocytes and diabetic mice. However, in Tlr4-deleted mice, which
exhibited delayed wound healing, the therapeutic beneﬁt of recombinant sTM was abrogated. Moreover, our
results showed that tumor necrosis factor-α (TNF-α) expression in keratinocytes was dose-dependently
upregulated by glucose, and TNF-α treatment downregulated the expression of TM and TLR4. Taken together,
high-glucose environment reduces the expression of TM and TLR4 in keratinocytes possibly through the action
of TNF-α, and recombinant sTM can increase the TLR4 expression and promote wound healing under diabetic
condition.
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INTRODUCTION
An explosive global increase in the number of people diagnosed
with diabetes mellitus has occurred during the past 20 years, and
more than 340million people were diagnosed with the disease
in 2011 (Zimmet et al., 2001; Danaei et al., 2011). Chronic limb
ulcer, a major complication of diabetes, occurs in 15% of the
diabetic patients and precedes 84% of diabetes-related amputa-
tions (Brem and Tomic-Canic, 2007). One of the well-known
causes of this complication is impaired cutaneous wound
healing (Goodson and Hung, 1977). To date, wound healing in
diabetes remains difﬁcult. Understanding the possible
mechanisms of deﬁcient wound recovery is important and
may lead to the development of effective therapies.
Evidence has indicated that high-glucose conditions can
modulate thrombomodulin (TM) expression in human aortic
endothelial cells and mouse glomerular capillaries (Isermann
et al., 2007; Wang et al., 2012). However, the alteration of
TM expression patterns in intact and injured skin under
diabetic conditions has not been characterized. Whether this
alteration contributes to the development of diabetic ulcer
remains to be investigated. Previous studies have suggested
that TM, a membrane glycoprotein, is tightly regulated during
keratinocyte differentiation and wound healing (Raife et al.,
1998). The protein structure of TM contains ﬁve functional
domains from amino- to carboxyl-terminal, including the
following: an NH2-terminal lectin-like region (TM domain
(TMD)-1), an EGF-like domain consisting of six EGF-like
repeats (TMD2), an O-glycosylation site-rich domain (TMD3),
a transmembrane domain (TMD4), and a cytoplasmic tail
(TMD5). Our studies have demonstrated that soluble TM
(sTM) is released by the rhomboid serine protease, and
recombinant TM domains 1, 2, plus 3, and 2 plus 3 (rTMD123
and rTMD23, respectively) may hold therapeutic potential to
promote cutaneous wound healing (Cheng et al., 2013). In
addition, circulating heterogeneous sTM fragments in the
plasma are elevated in cardiovascular disease, inﬂammatory
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endothelial injuries, and diabetes (Ohlin et al., 2005).
However, the impact of epithelial TM in diabetic wound
healing remains to be elucidated.
Toll-like receptors (TLRs) are engaged in pathogen recogni-
tion and the mediation of adaptive and innate immunity
(Medzhitov et al., 1997; Takeda and Akira, 2005). Many
TLRs, including TLRs 1–6 and TLR9, have been identiﬁed in
keratinocytes (Lebre et al., 2007). Among them, TLR4 is
involved in the inﬂammatory response in wound healing and
burn injury (Bettinger et al., 1994; Jobin et al., 2000).
Furthermore, TLR4 has an important role in the early stage
of cutaneous wound healing (Chen et al., 2013). Although
many studies have implicated TLRs in inﬂammation and
diabetes (Kim, 2006; Dasu et al., 2010), the roles of TLR4
expression in the epithelium in diabetic wound healing
remain to be investigated.
Tumor necrosis factor-α (TNF-α) is a cytokine released by
mononuclear cells during wound healing (Schirren et al., 1990)
and has been a therapeutic target for impaired cutaneous
wound healing (Ashcroft et al., 2012). In addition, TNF-α may
decrease TM expression in endothelial cells (Nan et al.,
2005). Human keratinocytes have been recognized as a
source of TNF-α under stimulation with endotoxins or UV
light (Kock et al., 1990). Under high-glucose conditions,
however, it is not clear whether TM and TLR4 expression is
regulated by TNF-α.
Using high-glucose cultured keratinocytes, a diabetic mouse
model, and Tlr4-deleted (TLR4del) mice, we investigated the
expression and regulation of TM and TLR4 in in vitro and
in vivo responses to injured diabetic skin. We also evaluated
the expression pattern of TNF-α in a high-glucose environ-
ment and explored the possible regulatory relationship
between TM, TLR4, and TNF-α in impaired diabetic wound
healing.
RESULTS
Downregulation of TM and TLR4 and reduction of sTM
production in keratinocytes in a high-glucose environment
To investigate the impact of a high-glucose environment on
TM and TLR4 expression in keratinocytes, we incubated
HaCaT cells, a human keratinocyte cell line, with various
concentrations of glucose and mannose. The protein expres-
sion of TM and TLR4 in HaCaT cells cultured with increasing
concentrations of glucose was downregulated in a dose-
dependent manner. This suppressive effect was not observed
in HaCaT cells cultured with mannose (Figure 1a). Similarly,
the protein expression levels of TM and TLR4 were signi-
ﬁcantly lower in skin keratinocytes obtained from diabetic
patients than in those obtained from healthy individuals
(Figure 1b). In addition, wound stimulation promoted sTM
production and upregulated the expression of TM and TLR4
when cells were cultured with 5.5 mM glucose. However,
these effects were abolished when the cells were cultured in a
high-glucose (50 mM) environment (Figure 1c). These results
demonstrated that high-glucose environments cause the
downregulation of TM and TLR4 and diminish the release of
sTM, even after stimulation with a scratch wound.
Decrease in TM expression and sTM production in the epidermis
of diabetic mice
We explored the patterns of epithelial TM expression and sTM
production in vivo. After a wound was created on streptozo-
tocin (STZ)-induced diabetic mice, samples of the wound
margin and unwounded skin were harvested for further analysis.
Immunoﬂuorescence staining showed that TM expression in the
unwounded skin of diabetic mice was signiﬁcantly lower than
that in controls (Figure 2a). After injury, TM expression
increased most prominently in the hyperproliferative epithelium
in control mice (Figure 2a). On the contrary, the wound-
induced upregulation of epidermal TM in the diabetic mice was
abolished on days 3 and 5 after wounding (Figure 2a and b). In
addition, analysis of the conditional medium from the skin
culture showed that the diabetic mouse skin did not produce
sTM (Figure 2c). These results, compatible with those of in vitro
studies, suggested that TM has a critical role in impaired
diabetic wound healing.
Human rTMD23 improves wound healing and ameliorates TLR4
downregulation of keratinocytes under high-glucose conditions
Our previous report suggested that sTM fragments
released from keratinocytes promote cutaneous wound
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Figure 1. High-glucose environment inhibits the expression of
thrombomodulin (TM) and Toll-like receptor 4 (TLR4) and reduces the
production of soluble thrombomodulin (sTM) in both basal and injury-
stimulated keratinocytes. (a) Western blot analysis of TM and TLR4 levels in
human keratinocyte cell line (HaCaT) cells cultured with various sugar
concentrations. Mannose as osmolarity control. (b) Determination of TM and
TLR4 protein levels in cell lysates of primary keratinocytes isolated from
diabetic patients. (c) Detection of the expression of the indicated proteins in
HaCaT cells with or without scratch wound stimulation. GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; Lys, lysate; Med, conditional
medium. Representative ﬁgures from three independent experiments
are shown.
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healing (Cheng et al., 2011). To evaluate more thoroughly the
effects of TM on high-glucose-impaired wound healing, we
used human rTMD23, which promotes wound healing in a
manner similar to that of rTMD123 (Cheng et al., 2013), to
treat high-glucose-maintained HaCaT cells. Using a
scratch wound healing assay, we found that treatment with
rTMD23 (20 and 200 ngml− 1) signiﬁcantly enhanced wound
recovery at 72 hours after treatment (Figure 3a and b).
Moreover, rTMD23 signiﬁcantly promoted TLR4 expression
in a dose-dependent manner after treatment for 24 hours
(Figure 3c and d). Consistent with previous observations,
these results suggested that sTM increases TLR4 expression on
keratinocytes and promotes wound healing in a high-glucose
environment.
Mouse rTMD23 improves wound healing and enhances TLR4
expression in diabetic mice
To evaluate whether sTM promotes diabetic wound healing
in vivo, we used mouse rTMD23 to treat wounds on STZ mice
via subcutaneous injection. Consistent with the results of
in vitro studies, the results of the incision wound healing assay
showed that treatment with rTMD23 accelerated wound
recovery in diabetic skin (Figure 4a and b). In addition, the
results of the analysis of wound margin skin specimens
obtained at 24 hours after the last rTMD23 injection revealed
a signiﬁcant dose-dependent upregulation of TLR4 expression
(Figure 4c and d). Taken together, these results suggested that
sTM accelerates diabetic wound healing both in vivo and
in vitro and that TLR4 has a role in the wound healing process.
Mouse rTMD23 fails to improve wound healing in TLR4del mice
TLR4del mice were used to investigate whether the promotion
of wound recovery by recombinant TM fragments depends on
TLR4 signaling. In the absence of TLR4, no difference
between the phosphate-buffered saline-treated control group
and the rTMD23-treated group was observed in the results of
the wound recovery assay (Figure 5a and b), suggesting that
the therapeutic beneﬁt of recombinant TM fragments on
diabetic skin wound healing occurs via a TLR4-dependent
pathway.
High glucose induces upregulation of TNF-α that may lead to
TM and TLR4 downregulation
We investigated whether the downregulation of TM and TLR4
under high-glucose conditions occurs through TNF-α. The
results showed that the TNF-α protein level was elevated by
glucose in a dose-dependent manner (Figure 6a). In addition,
treatment of TNF-α antibody signiﬁcantly attenuated the
downregulation of TM in HaCaT cells under a high-glucose
(50mM) condition (Figure 6b). Moreover, treatment with TNF-
α dose-dependently inhibited the expression of TM and TLR4
in normal glucose (5.5 mM)-cultured HaCaT cells (Figure 6c).
Conversely, wound-triggered TLR4 protein upregulation was
abolished in TM-stable silenced HaCaT cells (Figure 6d).
Taken together, these results show that high-glucose-induced
downregulation of TM and TLR4 in keratinocytes may occur
via TNF-α signaling and results in delayed wound healing
(Figure 6e).
DISCUSSION
Diabetes is a worldwide epidemic, and delayed wound
healing is a common problem in diabetic patients. Our
previous work has explored the therapeutic potential of sTM
and recombinant TM domains in the promotion of cutaneous
wound healing (Cheng et al., 2013). In this study, we focused
on the impact of TM and TLR4 on diabetic cutaneous wound
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Figure 2. Downregulated thrombomodulin (TM) expression, abrogated injury-triggered TM upregulation, and decreased soluble thrombomodulin (sTM)
production in streptozotocin (STZ)-induced diabetic mouse skin. (a) Incision wounds in the back skin of control and STZ mice were examined. Sections from the
control and STZ mice were stained with TMD1 antibody (green) and 4’,6 diamidino-2-phenylindole (DAPI; blue). The red dotted lines mark the hyperproliferative
epithelium (HE). D, dermis. Scale bar=200 μm. (b) Western blot analysis of TM levels in the skin samples from sodium citrate–treated (control) or STZ-treated
mice. (c) Western blot analysis of sTM production in the conditional medium of primary cultured skin tissue. GST, glutathione S-transferase. Representative ﬁgures
from three independent experiments are shown.
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healing. These observations may help clarify the signiﬁcance
of TM in diabetic wounds and also highlight the therapeutic
potential of sTM in diabetic cutaneous wound healing.
Elevated glucose levels and glucose homeostatic dysregu-
lation are the central etiologies in both type 1 and type 2
diabetes (Wertheimer et al., 2001). Increased plasma TM
antigen levels are observed in diabetic mice (Nakano et al.,
2000). Our previous studies showed that epithelial TM has a
pivotal role in keratinocyte differentiation and cutaneous
wound healing (Cheng et al., 2013). In this study, experi-
mental models—such as high-glucose incubated keratino-
cytes, tissue lysates of diabetic patient skin, and STZ-induced
diabetic mice—that simulate diabetic skin conditions were
used to evaluate the expression pattern of TM in response to
skin injuries. The results of in vitro and in vivo experiments
demonstrated that high glucose suppressed the expression of
epithelial TM and abolished the injury-triggered upregulation
of TM expression and sTM production in keratinocytes.
Because keratinocytes release sTM, and recombinant TM
fragments may enhance wound healing (Cheng et al., 2011),
the results of our study may provide an explanation for the
frequent impairment of wound healing in diabetic patients.
TM and TLR4 expression has an essential role in cutaneous
wound healing, and both factors are expressed in similar
spatiotemporal patterns after skin injury (Cheng et al., 2011;
Chen et al., 2013). However, the expression of TLR4 in
diabetic skin is unclear. In this study, we demonstrated that
TM and TLR4 expression decreased under high-glucose
conditions in cell culture and in diabetic patients. Treatment
with recombinant TM fragments increased the TLR4 protein
expression that was downregulated in the high-glucose state.
The promoting effects of recombinant TM fragments in wound
healing were not observed in TLR4del mice, suggesting
that TLR4 may be a downstream mediator of TM in wound
healing.
There is evidence demonstrating the role of TNF-α in
insulin resistance in diabetes and associated obesity. The
expression of TNF-α is elevated in adipose tissue analyzed
using multiple experimental models of obesity (Hotamisligil
et al., 1995). In addition, TNF-α expression in muscle tissue
obtained from insulin-resistant and diabetic subjects is higher
than that in controls, suggesting that the upregulation of TNF-
α may be one of the underlying pathologic events in systemic
insulin resistance (Saghizadeh et al., 1996; Moller, 2000).
Recent studies have further explored the link between TNF-α
and impaired diabetic wound healing. Increased TNF-α
expression in diabetic wounds impairs healing, possibly
owing to enhanced ﬁbroblast apoptosis and decreased
proliferation, whereas TNF-α inhibition increases ﬁbroblast
density and improves healing in diabetic mice (Siqueira et al.,
2010). The results of our studies showed that high-glucose
environments reduce TM expression on keratinocytes and
may occur through the TNF-α signaling pathway. The results
in this report showed that TNF-α treatment decreases the
expression of TM in keratinocytes when cultured in normal-
glucose medium and that anti-TNF-α antibody rescues the
decreased TM expression in cultures with high-glucose
medium. These observations are consistent with the hypoth-
esis that high glucose induces TNF-α production through an
unidentiﬁed mechanism that in turn inhibits TM expression in
keratinocytes and therefore contributes to the impairment of
wound healing in diabetic patients.
Our study has some limitations. First, although TLR4 may
be a downstream mediator of TM in wound healing, the
results observed in TLR4del mice might reﬂect a strain differ-
ence as much as the knockout effect. These ﬁndings can be
supported by supplemental experiments, such as in vitro
studies using primary cultured TLR4del keratinocytes or TLR4-
silenced HaCaT cells. Further studies are warranted to
determine the detailed molecular mechanisms by which
TM modulates TLR4 and downstream signaling pathways.
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Figure 3. Human recombinant thrombomodulin domains 2 plus 3 (rTMD23)
promotes wound recovery and Toll-like receptor 4 (TLR4) expression in high-
glucose-cultured human HaCaT cells. (a) Wound recovery assay in high-
glucose-cultured HaCaT cells treated with various doses of rTMD23 for
72 hours. White dotted lines indicate the wound borders at the start of the
assay. FBS, fetal bovine serum. (b) Quantitative representation of a. (c) Western
blot analysis of TLR4 levels in high-glucose-cultured HaCaT cells treated with
rTMD23 for 24 hours at the indicated concentrations. (d) Quantitative
representation of c. *Po0.05; **Po0.01, (n=3).
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Second, TLR4 is a molecular link between nutrition, lipids,
and inﬂammation and participates in the development of
insulin resistance in insulin target tissues, such as adipocytes
and macrophages (Shi et al., 2006). However, we found that
TLR4 expression was reduced in diabetic keratinocytes and
TLR4 mediated the therapeutic effect of TM on diabetic
wound healing. The differential roles of TLR4 in the patho-
genesis of diabetes and diabetes-related complications are an
interesting issue for future studies.
Exploring the underlying mechanisms responsible for
impaired diabetic wound healing is a matter of urgent
public importance. In conclusion, the downregulation of TM
and TLR4 by TNF-α may represent a mechanism for the
impairment of wound healing in diabetes. The linking of TM
with epidermal inﬂammatory response may also provide a
potential therapeutic option to prevent or treat diabetic ulcers.
MATERIALS AND METHODS
Reagents
Anti-TLR4 and TNF-α neutralization antibodies were purchased from
Abcam (Cambridge, MA). Anti-TM, anti-glyceraldehyde 3-phosphate
dehydrogenase, anti-glutathione S-transferase, anti-tubulin, and anti-
β-actin antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). STZ, glucose, mannose, and puriﬁed TNF-α were
purchased from Sigma (Sigma Chemical, St Louis, MO). Normal
and diabetic human primary keratinocytes were purchased from
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Figure 4. Mouse recombinant thrombomodulin domains 2 plus 3 (rTMD23) promotes Toll-like receptor 4 (TLR4) expression and accelerates wound healing in
streptozotocin (STZ) mouse skin. (a) Cutaneous wound healing assay in STZ mice treated with phosphate-buffered saline (PBS) or rTMD23 (125mg kg−1). Scale
bar=4mm. (b) Quantitative representation of a (n= 5). (c) Detection of TLR4 expression with western blotting analysis. The skin from the wound margin was
sampled 24 hours after the last rTMD23 injection. Representative results from three independent experiments are shown. (d) Quantitative representation of c.
*Po0.05; **Po0.01.
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Figure 5. Mouse recombinant thrombomodulin domains 2 plus 3 (rTMD23) fails to promote wound recovery in Tlr4-deleted (TLR4del) mice. (a) Incision wound
recovery analysis of the back skin of TLR4del mice treated with phosphate-buffered saline (PBS) or rTMD23 on days 2 and 3 after injury. Scale bar=5mm.
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Lonza (Anaheim, CA). As described previously, mouse and human
rTMD23 were puriﬁed with a nickel-chelating Sepharose column
(Amersham Pharmacia Biotech, Piscataway, NJ) and eluted under
sterile conditions (Shi et al., 2005).
Mouse strains and wound model
In this study, 6- to 8-week-old C57BL/10ScNJ TLR4del and wild-type
C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were used. The
incision wound model was performed as described previously
(Tsuboi and Rifkin, 1990) with modiﬁcations. The wound margins
were treated with the recombinant TM proteins at the indicated doses
via subcutaneous injection once per day on days 2 and 3 after injury.
The wounds were photographed daily for 7 days, and the wound
sizes were determined with ImageJ software (National Institutes of
Health, Bethesda, MD). The percentage of daily wound closure
was compared with the original wound area on day 1 after wound
generation (Greenhalgh et al., 1990). All animal experiments were
approved by the Institutional Animal Care and Use Committee of
National Cheng Kung University (Tainan, Taiwan).
STZ mouse model
Wild-type C57BL/6 mice (7 weeks) were divided into two groups:
normal control group and induced diabetes group. Diabetic mice were
induced with a single intravenous injection of STZ (150mg kg−1)
dissolved in 50mM citrate, pH 4.7. Control mice were injected with
citrate buffer alone. The glucose content was measured with a
glucose kit (Randox, Crumlin, UK) according to the manufacturer’s
instructions. The blood glucose concentration of diabetic mice
should be 413.9 mM (250mg dl−1).
Murine skin culture
Punch biopsies (6 mm) were prepared under sterile conditions from
the back skin of control and diabetic mice according to previously
described protocols (Spiekstra et al., 2007). After culture for 24 hours,
the conditioned medium was concentrated using Centricon tubes
(Amicon, Beverly, MA), and glutathione S-transferase was added
(20 μg per sample) as an internal control. The concentrated samples
were then subjected to western blot analysis.
Cell culture
The HaCaT human keratinocyte cell line was grown in DMEM that
contained various glucose concentrations (5.5, 12.5, 25, or 50 mM)
and was supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA). Clinically, the blood glucose level in healthy indivi-
duals is ∼4–8mM (72–144mg dl−1). In diabetic conditions, the glucose
concentration is 412mM (200mg dl−1) (American_Diabetes_
Association, 2008). Cells were plated in 6-well plates (3× 105 cells
per well) for experiments.
In vitro wound healing assay
As described previously, the cells were photographed using a
microscopy system (Olympus, Tokyo, Japan) immediately after the
wounds were made (Cheng et al., 2011). The rate of wound recovery
was quantitatively determined with ImageJ software. The percentage
of wound recovery at the indicated time points was calculated by
comparing with the original wound area.
TM-stable silenced HaCaT cells
TM gene silencing in HaCaT cells was accomplished by using short
hairpin RNA technology (Kao et al., 2010). The short hairpin–
transfected cells were selected with 1 μgml− 1 puromycin for
43 weeks.
Western blot analysis
Tissue or cells were lysed and western blot analysis was performed as
previously described (Cheng et al., 2011). Approximately 50 μg total
protein was separated in a 10% SDS-PAGE and transferred onto a
polyvinylidene diﬂuoride membrane. After probing with a primary and a
secondary antibody, the signal was detected using an enhanced chemi-
luminescence reagent (Amersham Pharmacia Biotech). The western blot
assays were representative of three independent experiments.
Histology
Skin samples were excised from the dorsal area of the mice at the
indicated time points after injury. For frozen sections, samples were
embedded in tissue-freezing embedding medium and frozen at − 80 °
C overnight. Frozen sections 10 μm thick were stained with 4’,6
diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) or
the indicated antibodies. Secondary antibodies conjugated with
Alexa Fluor 488 (Molecular Probes, Eugene, OR) were used for
immunoﬂuorescence staining.
Statistical analysis
Data are expressed as means± SD. Statistical signiﬁcance was
analyzed using one-way analysis of variance or Student’s t-test.
The P-values of o0.05 were considered statistically signiﬁcant.
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